Drug Profile
mRNA 3704
Alternative Names: mRNA-3704Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class RNA
- Mechanism of Action Methylmalonyl CoA mutase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Methylmalonic acidaemia
Most Recent Events
- 17 Sep 2020 Discontinued - Phase-I/II for Methylmalonic acidaemia (In adolescents, In children, In infants, In adults) in United Kingdom (IV)
- 17 Sep 2020 Discontinued - Phase-I/II for Methylmalonic acidaemia (In adolescents, In children, In infants, In adults) in USA (IV)
- 29 Mar 2020 Moderna Therapeutics temporary halts the recruitment in a phase-I/II trial for Methylmalonic acidaemia (In adolescents, In children, In infants, In adults) in United Kingdom and USA (IV) due to impact of COVID-19 (NCT03810690)